Oncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic Alternatives

7 days ago

SAN DIEGO, Sept. 12, 2024 ( GLOBE NEWSWIRE ) -- Oncternal Therapeutics, Inc. ( Nasdaq: ONCT ) ( the "Company" ) today announced its decision to discontinue its clinical trials evaluating ONCT-534, its dual action androgen receptor inhibitor for the treatment of patients with metastatic ...

Ticker	Sentiment	Impact
ONCT	Somewhat Bearish	57 %